Dicloxacillin

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Dicloxacillin
    1. Pharmacist Assessment Report
    2. Dicloxacillin: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Dicloxacillin: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Dicloxacillin, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are existing records, not model candidates.

Quick overview

Item Content
New predicted indications None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug 3
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
staphylococcal infection
staphylococcal pneumonia
staphylococcus aureus infection

Australia Market Information

Licence Product Dosage form Status
10790X Distaph 500 Capsule 500 mg (as sodium) Valid

Safety Considerations

No label-based warnings or contraindications are available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

  • Knowledge-graph contraindication associations (these are not label text): kidney disease, pyoureter, Clostridium difficile colitis, perinatal necrotising enterocolitis, infectious mononucleosis, and chronic Epstein-Barr virus infection syndrome.
  • Drug interactions: 41 interactions were identified in total. The most notable are rated Moderate:
    • Tetracyclines: doxycycline, tetracycline, minocycline
    • Balsalazide
    • Picosulfuric acid
    • Iodide I-131
  • Minor: clarithromycin.
  • Unknown severity: several others, including proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), ranitidine, corticosteroids (prednisone, dexamethasone, triamcinolone), morphine, loperamide, ondansetron, metronidazole, misoprostol and rosuvastatin.
  • Pharmacokinetic note: dicloxacillin is highly albumin-bound, so conditions affecting albumin may alter free-drug levels. A published case also describes subtherapeutic levels in a neonate.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



This site uses Just the Docs, a documentation theme for Jekyll.